Meeting of the microbiomes

Behind Flagship's decision to merge two immuno-microbiome portfolio companies

When Flagship Ventures created two immuno-microbiome companies two years ago, the biology was so new that the firm didn't fully know what it had. Now, Flagship is merging cancer-focused Evelo Biosciences Inc. and autoimmune and inflammatory play Epiva Biosciences

Read the full 397 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE